Introduction

Dust‑mite allergy is year‑round and commonly managed with immunotherapy to retrain the immune system. From home, patients typically choose among: (1) the FDA‑approved house‑dust‑mite sublingual tablet (Odactra), (2) custom sublingual allergy drops (SLIT, off‑label in the U.S.), or (3) traditional allergy shots (SCIT, in‑office). This page compares these options and highlights the boxed‑warning requirements for Odactra so you can choose a safe, effective path with Wyndly’s physician‑led care.

Update (October 24, 2025): The FDA expanded Odactra’s indication to ages 5–11 on Feb 28, 2025; Odactra is now approved for individuals 5–65 years. First dose must be given under medical supervision and patients should be prescribed epinephrine.

What each option means

Odactra (HDM SLIT tablet)

A once‑daily tablet that dissolves under the tongue to treat house‑dust‑mite (Dermatophagoides farinae/pteronyssinus) allergic rhinitis with or without conjunctivitis. FDA‑approved for ages 5–65. First dose must be administered in a healthcare setting with ≥30 minutes of observation; an epinephrine auto‑injector should be prescribed and patients/guardians trained. Contraindications include severe/unstable/uncontrolled asthma, history of severe systemic or severe local reaction to SLIT, eosinophilic esophagitis, or relevant hypersensitivity.

Sublingual allergy drops (custom SLIT)

Physician‑directed liquid allergen extracts placed under the tongue daily. In the United States, liquid SLIT drops are not FDA‑approved; they are an off‑label option some clinicians use. Evidence exists, but dosing and mixtures vary; professional societies note that liquid SLIT is not FDA‑approved in the U.S.

Allergy shots (SCIT)

Allergen extracts injected subcutaneously in a clinic: weekly build‑up for months, then maintenance every 2–4 weeks for 3–5 years. SCIT is established, treats multiple allergens in one regimen, and typically shows meaningful benefits after ~6–12 months; each injection requires an observation period because of rare but serious reactions.

Boxed‑warning facts for Odactra (read before deciding)

• Severe allergic reactions (including anaphylaxis and severe laryngopharyngeal restriction) can occur; first dose must be given under healthcare supervision with ≥30 minutes of observation.

• Prescribe an epinephrine auto‑injector; instruct and train the patient/guardian in its use and to seek immediate medical care after use.

• Contraindicated in severe/unstable/uncontrolled asthma; in those with prior severe systemic or severe local SLIT reactions; in eosinophilic esophagitis; or with hypersensitivity to ingredients.

• Approved ages: 5–65 years (dust‑mite allergic rhinitis with/without conjunctivitis), not indicated for immediate symptom relief.

At‑a‑glance comparison

Dimension	Odactra tablet (HDM)	Sublingual drops (custom SLIT)	Allergy shots (SCIT)
FDA status (U.S.)	FDA‑approved (ages 5–65) for dust‑mite rhinitis ± conjunctivitis	Not FDA‑approved; off‑label in U.S.	Established in‑office therapy
First dose & supervision	First dose in clinic; ≥30‑min observation; epinephrine prescribed	No FDA label; clinician‑directed protocols; typically home dosing	Every injection in clinic with post‑shot observation
Where you dose	Home (after first dose)	Home	Clinic
Allergens treated	Single: house dust mite	Often multi‑allergen (per clinician protocol)	Multi‑allergen
Typical course	Daily, often 3 years	Daily, often 3–5 years	Weekly build‑up → monthly maintenance; 3–5 years
Onset of noticeable benefit	Variable; weeks to months	Often 3–4 months (varies by protocol)	Commonly ~6–12 months
Key safety notes	Boxed warning; epinephrine required; specific contraindications	Not FDA‑approved; safety generally favorable but dosing varies	Rare systemic reactions; clinic monitoring required

Sources: FDA label/website; AAAAI/ACAAI public guidance; Harvard Health and academic summaries.

Who might prefer which option?

• Choose Odactra if you want an FDA‑approved, at‑home tablet targeting dust mites and you can complete the supervised first dose, carry epinephrine, and meet label criteria (ages 5–65; no listed contraindications).

• Consider custom SLIT drops if you prefer at‑home dosing and need multi‑allergen treatment, recognizing they are off‑label in the U.S. and require physician oversight to balance benefits and uncertainties in standardized dosing.

• Stick with allergy shots if you want long‑standing, multi‑allergen therapy with robust evidence and insurance familiarity, and you can commit to clinic visits and the typical 6–12‑month horizon for benefit.

Safety, eligibility, and monitoring—key details

• Epinephrine: FDA‑approved SLIT tablets (including Odactra) require prescribing epinephrine for home use and training on when/how to use it.

• Age: Odactra is approved for ages 5–65 (expanded in 2025 to include 5–11‑year‑olds).

• Asthma and EoE: Avoid SLIT tablets in severe/unstable/uncontrolled asthma or eosinophilic esophagitis; discuss any history of severe SLIT reactions.

• Shots: Expect observation after each injection and a gradual build‑up to maintenance; serious reactions are uncommon but possible.

How Wyndly supports each path

• Physician‑led, from home: Wyndly’s board‑certified doctors diagnose environmental allergies and design immunotherapy you can take at home. We use FDA‑approved tablets when indicated (e.g., Odactra for dust mites) or clinically guided, personalized SLIT drops for multi‑allergen care, and we coordinate in‑person care when shots are the better fit.

• Transparent expectations: We counsel on boxed‑warning requirements, epinephrine use, and contraindications before starting any SLIT tablet, and we monitor progress throughout the 3‑year course common to immunotherapy.

FAQs

Is Odactra right for children? Yes, if they’re 5–65 years old and meet label criteria. The first dose must be supervised; families must keep and know how to use epinephrine.

Can SLIT drops replace shots? Drops are off‑label in the U.S.; many clinicians use them, especially for multi‑allergen regimens. Discuss goals, safety, and evidence with your physician.

How long until I feel better? Expect weeks to months with SLIT (tablets or drops), and roughly 6–12 months with shots; full courses commonly last 3–5 years for durable benefit.

Who should avoid SLIT tablets? People with severe/unstable/uncontrolled asthma, eosinophilic esophagitis, or prior severe SLIT reactions; review all medications (e.g., beta‑blockers) with your clinician.

---

Next steps with Wyndly

• Start with an at‑home, CLIA‑certified allergy test and a video visit.

• Your doctor will confirm dust‑mite sensitivity and discuss Odactra vs drops vs shots, including boxed‑warning requirements and monitoring.

• We tailor dosing, follow safety protocols for the first tablet dose (if applicable), and support you throughout therapy.